Data for: Proteomics reveal biomarkers for diagnosis, disease activity and long-term disability outcomes in multiple sclerosis
The concentration of 1463 proteins were measured using the Olink Explore platform which uses Proximity Extension Assay (PEA) technology. The proteins are preselected from four Olink panels: Explore 384 Cardiometabolic, Explore 384 Inflammation, Explore 384 Neurology, and Explore 384 Oncology. The protein concentrations are given as Olink’s relative protein quantification unit on log2 scale: Normalized Protein Expression (NPX). The NPX values were intensity normalized by Olink. Protein levels were measured in cerebrospinal fluid samples (n = 186) and plasma samples (n = 165) from persons with multiple sclerosis and healthy controls. The dataset was originally published in DiVA and moved to SND in 2024.
Åkesson, J., Hojjati, S., Hellberg, S., Raffetseder, J., Khademi, M., Rynkowski, R., … Gustafsson, M. (2023). Proteomics reveal biomarkers for diagnosis, disease activity and long-term disability outcomes in multiple sclerosis. Nature Communications, 14(1). https://doi.org/10.1038/s41467-023-42682-9
Department of Physics, Chemistry and Biology
Department of Biomedical and Clinical Sciences
European Union's Marie Sklodowska-Curie
Swedish Foundation for Strategic Research
Medical Research Council of Southeast Sweden
Specific diseases, disorders and medical conditions
Data on specific, diagnosed diseases, disorders or syndromes (often classified in ICD-10 or its earlier versions). For example, medical research on infectious diseases or the causes of diabetes, or data on the physical and mental recovery of people who have had heart surgery.
Bioinformatics and Computational Biology
The systematic study of the complete complement of proteins (PROTEOME) of organisms.